The e-text is designed to provide a clear explanation of the basic facts how new medicines for the Alzheimer' disease are tested. The e-text is currently accessed by a password issued to subscribers, though a new on- and offline reading system will be introduced soon.

The sections (or chapters) are as follows:

1. Foreword
2. Introduction
3. Brain Basics
4. Pathophysiology
5. Symptoms
6. Diagnostic criteria and tests
7. Current treatments
8. Symptomatic vs disease modifying approaches
9. Regulatory Guidelines
10. Clinical Trial Design and Phases
11. Endpoints: clinical
12. Endpoints: biochemical
13. Endpoints:neuroimaging, other
14. Key trial methodology issues
15. Prevention studies
16. Combination studies
17. Appendix

The e-text is intended to be useful to anyone needing a concise summary about  how new treatments for Alzheimer's disease are developed. Background information on the condition itself is included to the extent needed for understanding the development aspects. Finally a short chapter on the basics of brain function has also been included for those new to this area.

 

 

 

 

 

 

 

 

Dr Gray publishes article with Professor Winblad and David Fleet on need for thorough Phase II studies in AD medicines development - Link

Dr Gray presents poster on use of repeated measures analysis in small studies in AD at ADPD meeting Nice March 18-22-2015

EMA workshop on clinical investigation of medicines for treatment of AD held November 24-25 2014 in London presentations available here